Human-growth hormone injection-related Creutzfeldt-Jakob Disease (Q92020): Difference between revisions

← Older edit

@@ Property / CURIE @@
+CID11:ID_866329807
@@ Property / CURIE: CID11:ID_866329807 / rank @@
+Normal rank
@@ Property / Canary Token @@
+dki-india-ID_866329807
@@ Property / Canary Token: dki-india-ID_866329807 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-15T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-15T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 15 August 2026 / rank @@
+Normal rank

Latest revision as of 07:10, 16 August 2026

Human growth hormone-related Creutzfeldt-Jakob Disease (CJD) is CJD in patients treated with human growth hormone derived from the pituitary glands in the brains of cadaveric donors. The clinical features include progressive cerebellar ataxia and a longer disease course than classical sCJD. After the prohibition of the cadaveric use for growth hormone, the occurrence of CJD in this manner has been drastically reduced.

Language	Label	Description	Also known as
default for all languages	ID_866329807
English	Human-growth hormone injection-related Creutzfeldt-Jakob Disease	Human growth hormone-related Creutzfeldt-Jakob Disease (CJD) is CJD in patients treated with human growth hormone derived from the pituitary glands in the brains of cadaveric donors. The clinical features include progressive cerebellar ataxia and a longer disease course than classical sCJD. After the prohibition of the cadaveric use for growth hormone, the occurrence of CJD in this manner has been drastically reduced.